Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 6, 2005, Pages 340-343

  Atmaca, A ^a   Erbas, Tomris ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acromegaly; Insulin; Lipoatrophy; Octreotide; Side effect

Indexed keywords

INSULIN; OCTREOTIDE;

ACROMEGALY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; DISEASE PREDISPOSITION; DOSE RESPONSE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPOPHYSIS ADENOMA; INJECTION SITE; LIPOATROPHY; LONG TERM CARE; PATHOGENESIS; PATIENT MONITORING; PH; PRIORITY JOURNAL; STEREOTAXIC SURGERY; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ADULT; ATROPHY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LIPODYSTROPHY; MIDDLE AGED; OCTREOTIDE; SUBCUTANEOUS TISSUE;

EID: 21244434891     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837664     Document Type: Article

References (20)

1. Ampudia-Blasco FJ, Hasbum B, Carmena, R. A new case of lipoatrophy with lispro insulin in insulin pump therapy. Is there any insulin preparation free of complications? Diabetes Care 2003; 26: 953-954
2. Atlan-Gepner C, Bongrand P, Farnarier C, Xerri L, Choux R, Gauthier JF, Brue T, Vague P, Grob JJ, Vialettes B. Insulin-induced lipoatrophy in type 1 diabetes. A possible tumor necrosis factor-α-mediated dedifferentiation of adipocytes. Diabetes Care 1996; 19: 1283-1285
3. Chantelau E, Reuter M, Schotes S, Starke AAR. A case of lipoatrophy with human insulin-therapy. Exp Clin Endocrinol 1993; 101: 194-196
4. Davies PH, Stewart SE, Lancranjan I, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly. Clin Endocrinol 1998; 48: 311-316
5. Drago F, Rongioletti F, Battifoglio ML, Rebora A. Localised lipoatrophy after acupuncture. Lancet 1996; 347: 1484
6. Garg A. Lipodystrophies. Am J Med 2000; 108: 143-152
7. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy. An old complication, a new cause? Diabetes Care 2001; 24: 174
8. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104: 106-110
9. Jaap AJ, Horn HM, Tidman MJ, Walker JD. Lipoatrophy with human insulin. Diabetes Care 1996; 19: 1289-1290
10. Jermendy G, Nádas J, Sápi Z. "Lipoblastoma-like" lipoatrophy induced by human insulin: morphological evidence for local dedifferentiation of adipocytes? Diabetologia 2000; 43: 955-956
11. Kayikcioglu A, Mustafa A, Erk Y. Semicircular lipoatrophy after intragluteal injection of benzathine penicillin. J Pediatr 1996; 129: 166-167
12. Lami MC, Hadjadj S, Guillet G. Hair loss in three patients with acromegaly treated with octreotide. Br J Dermatol 2003; 149: 655-656
13. Lancranjan I, Atkinson AB, the Sandostatin®LAR® Group. Results of a European Multicentre Study with Sandostatin®LAR® in acromegalic patients. Pituitary 1999; 1: 105-114
14. Logwin S, Conget I, Jansa M, Vidal M, Nicolau C, Gomis R. Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device. Diabetes Care 1996; 19: 255-256
15. Melmed S. Somatostatin analogues: the breadth of applications and a look into the future. In: Lamberts SWJ (ed). Octreotide: The Next Decade. First Edition. Bristol, UK: BioScientifica Ltd, 1999: 9-25
16. Murao S, Kyoji H, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37: 1031-1033
17. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995; 80: 2768-2775
18. Priestley GC, Aldridge RD, Sime PJ, Wilson D. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin®) in vitro. Br J Dermatol 1994; 131: 52-56
19. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J 1980; 280: 1500-1503
20. van der Lely AJ, de Herder WW, Lamberts SWJ. A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Saf 1997; 17: 317-324